Key facts
- Notable investors include DRIVE ( KI Innovations Business Incubator), SU Holding.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Nexus Epigenomics
- ·The full record, as it builds
Funding rounds
No funding rounds for Nexus Epigenomics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nexus Epigenomics
Operator of an epigenetics platform intended to profile the different layers of the epigenome for a holistic understanding of gene regulation. The company offers versatile, easy-to-use technologies, enabling researchers and clinicians to efficiently target specific segments of gene regulation, advancing disease understanding and potential treatments.
- Sector
- Healthcare
- HQ
- Vällingby, Sweden
- Founded
- 2023
- Employees
- 2
- Website
- nexus-epigenomics.com/
- Ownership
- Privately Held (backing)
Nexus Epigenomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nexus Epigenomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nexus Epigenomics in its N-PORT filings yet. We sweep new filings monthly.